Common Contracts
6 similar Joint Filing Agreement contracts by Redmile Group, LLC
Joint Filing AgreementJoint Filing Agreement • February 14th, 2019 • Redmile Group, LLC • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.001 par value per share, of GlycoMimetics, Inc., which may be deemed necessary pursuant to Regulation 13D or 13G promulgated under the Exchange Act.
Joint Filing AgreementJoint Filing Agreement • February 14th, 2019 • Redmile Group, LLC • Surgical & medical instruments & apparatus
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.001 par value per share, of Endologix, Inc., which may be deemed necessary pursuant to Regulation 13D or 13G promulgated under the Exchange Act.
Joint Filing AgreementJoint Filing Agreement • February 14th, 2019 • Redmile Group, LLC • Biological products, (no disgnostic substances)
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.001 par value per share, of Scholar Rock Holding Corporation, which may be deemed necessary pursuant to Regulation 13D or 13G promulgated under the Exchange Act.
Joint Filing AgreementJoint Filing Agreement • February 14th, 2019 • Redmile Group, LLC • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.001 par value per share, of Clovis Oncology, Inc., which may be deemed necessary pursuant to Regulation 13D or 13G promulgated under the Exchange Act.
Joint Filing AgreementJoint Filing Agreement • February 14th, 2019 • Redmile Group, LLC • Insurance agents, brokers & service
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.001 par value per share, of ehealth, Inc., which may be deemed necessary pursuant to Regulation 13D or 13G promulgated under the Exchange Act.
Joint Filing AgreementJoint Filing Agreement • February 14th, 2019 • Redmile Group, LLC • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.001 par value per share, of Chimerix, Inc., which may be deemed necessary pursuant to Regulation 13D or 13G promulgated under the Exchange Act.
